Karolinska Development company Umecrine Cognition announces

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
133
Karolinska Development company Umecrine Cognition announces first patient included in clinical Phase Ib/IIa study with GR3027 for Hepatic Encephalopathy

STOCKHOLM - March 17, 2017. Karolinska Development's portfolio company Umecrine Cognition AB today announces the inclusion of the first patient in a clinical Phase Ib/IIa study of GR3027, which is in development as a potential new treatment for Hepatic Encephalopathy.  

Details from the Umecrine Cognition press release follow:

The objectives of the study (protocol UCAB-CT-02) are to evaluate the safety and pharmacokinetics of steady-state dosing in healthy adults and patients with cirrhosis, assess the potential efficacy of the GR3027 on cognitive function in patients with cirrhosis and covert HE, and determine the Phase IIb dose.

Liver disease accounts for a growing and substantial disease burden worldwide. Hepatic encephalopathy (HE) is a syndrome of impaired brain function that frequently occurs in patients with liver cirrhosis. Symptoms of HE range from subtly impaired cognition (covert HE) to confusion, decreased levels of consciousness to coma (overt HE). There are today no treatments available that directly target the brain abnormalities responsible for HE.

GR3027 is a GABA A receptor modulating steroid antagonist (GAMSA) designed to antagonize GABA A receptor activation by endogenous neuroactive steroids. GR3027 has been shown to improve or normalize cognitive function and learning in two models of HE. In a single ascending dose study in healthy volunteers, GR3027 exhibited satisfactory safety and linear PK, and a human challenge study further indicated that GR3027 enters the CNS and can reverse the inhibitory effects of the endogenous neurosteroid allopregnanolone on brain function. Collectively, the findings strongly implicate neurosteroid activation of GABA A receptors in the pathogenesis of HE and indicate that GR3027 shows promise as novel treatment for this disorder.

Magnus Doverskog, CEO of Umecrine Cognition, said: "Based on the encouraging results from the completed Phase Ia study in healthy volunteers, we are excited to start exploring GR3027 in patients with cirrhosis, a population in need of new treatments to improve the impaired neurological functions that severely affect their lives."

Viktor Drvota, Deputy CEO and Chief Investment Officer at Karolinska Development, said: "This is positive news for Umecrine Cognition, which has already seen encouraging early clinical results. Having also recently completed a successful financing round of SEK 45 million (US$4.9 million), the inclusion of the first patient in this Phase Ib/ IIa study is a step forward in the development of GR3027."

For further information, please contact:

Jim Van heusden, CEO, Karolinska Development AB Phone: +46 72 858 32 09, e-mail: jim.van.heusden@karolinskadevelopment.com 

Viktor Drvota, Deputy CEO and Chief Investment Officer, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson Phone: +44 20 7638 9571; e-mail: KDev@citigatedr.co.uk

TO THE EDITORS

About Umecrine Cognition AB Umecrine Cognition, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company, is developing a potential therapy that represents a new target class relevant for several major CNS-related disorders. The primary focus is to develop a treatment for life-threatening overt Hepatic Encephalopathy and long-term treatment in minimal Hepatic Encephalopathy in patients with liver disease, a growing area with high unmet medical need. The current lack of therapeutics that directly addresses the neurocognitive signs and symptoms of Hepatic Encephalopathy makes a novel treatment likely to become a major contribution for the treatment of this disorder. For more information, please visit www.umecrinecognition.com

About Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...5f5790afbe

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Teledyne LeCroy Drives AI Scale-up with New UALink

Updated Category News Views 0

Pushing the Boundaries of AI Infrastructure Teledyne LeCroy is shaking things up with their latest innovation—the Xena Z2244 Ultra Accelerator Link™ Traffic Generator, a tool that promises to turbocharge validation systems for AI and HPC scale-up infrastructure. If you're dealing with the nuts and bolts of next-gen networks, this one's worth your attention. Setting a...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 70

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 78

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 259

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 100

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
PolyBio Convergence Summit Tackles Aging, Chronic Illness

Updated Category News Views 25

Kicking Off The Convergence: Pathogens in Focus Here's a gathering that's set to challenge how we think about lingering illnesses and aging. PolyBio Research Foundation is bringing a powerhouse of brains to the table with their inaugural Convergence Summit. It's more than just science talk; it's a chance to push boundaries in understanding how pathogens stick around and...

Continue Reading
Peptide Tracker Refresh Unveils New Planning Features

Updated Category News Views 85

Peptide Tracker's Latest Updates: A Game Changer? I'll tell you what—if you're keeping tabs on your peptide intake like a seasoned gardener checks the soil, Peptide Tracker's fresh versions 3.2.0 and 3.3.0 might just be your new best mates. With the addition of washout scheduling and a robust six-month schedule preview, this isn't just another fancy tech update. It's...

Continue Reading
YYForce's Strategic Play: Robotics and AI Expansion

Updated Category News Views 28

Innovation Meets Pragmatism at YYForce There's a new bout of excitement brewing over at YYForce Inc. (NASDAQ: YFOR), if the latest announcements are anything to go by. The Singapore-based AI-enabled workforce dynamo is laying out priorities like a general plotting a campaign—pragmatic, strategic, and with a keen eye on the bottom line. Aiming for a Technological Edge In...

Continue Reading
MISUMI Americas Expands, Ventures into New Horizons

Updated Category News Views 59

Marking New Territory in Monterrey MISUMI Americas is planting a new flag down in Monterrey, Mexico, with a sprawling 45,000-square-foot facility. This isn't just another expansion; it's a strategic move that's bound to shake things up in the manufacturing sector south of the border. When you've got a player like MISUMI widening their footprint, it catches the eye. Why?...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 102

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading

Top 5 Most Recently Viewed Articles

Brave Healer Productions Unveils Transformational Book Series

Updated Category News Views 253

Brave Healer Productions Unveils Transformational Book Series Brave Healer Productions has made an exciting announcement with the introduction of Shaman Heart: We Are the Ones We've Been Waiting For, the third volume in the acclaimed Shaman Heart series. This significant release highlights the wisdom of 26 courageous healers, teachers, and spiritual mentors who embarked...

Continue Reading
Empowering Fans: Miss Universe Adopts Blockchain Voting App

Updated Category News Views 314

Revolutionizing Fan Engagement with Blockchain Technology In a historical move that blends tradition with technology, the Miss Universe Organization (MUO) has partnered with Zetrix to unveil the Miss Universe Global Blockchain Voting App. This strategic alliance aims to empower fans worldwide by facilitating secure and trustworthy voting experiences, marking a significant...

Continue Reading
Occidental Bets Big on Argentine Sunflower Boom

Updated Category News Views 64

The Sunflower Seed Gamble When a company like Occidental Resources plunks down $200 million for sunflower seeds, you sit up and take notice. We're talking 300,000 metric tons of those little yellow gems sourced from Argentina, which according to the Rosario Board of Trade, is rolling in a whopping 6.6 million metric tons of sunflower product this year. Doesn't sound like...

Continue Reading
Martini Market’s $MRT Presale: Last Chance to Seize the Opportunity

Updated Category News Views 207

The Exciting Conclusion of the Martini Market Presale As the highly anticipated $MRT token presale approaches its final days, the excitement is palpable in the decentralized finance (DeFi) community. With just a few days left, Martini Market has established itself as a frontrunner in the realm of decentralized prediction markets on the XRP Ledger. What Makes Martini...

Continue Reading
Samsara Intelligence: Transforming Operations with AI Power

Updated Category News Views 345

Revolutionizing Operations with Samsara Intelligence Samsara Inc. (NYSE: IOT), a trailblazer in the Connected Operations Cloud space, has just launched Samsara Intelligence. This sophisticated suite of AI offerings is crafted to assist businesses in making informed decisions, thereby streamlining operations while ensuring safety. Harnessing an extensive database that...

Continue Reading